All In Biotech

Drug Trial Radar · NCT07606365

A Study in Adults With Geographic Atrophy

A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 11, 2026

Primary completion

Jul 2028

Study completion Aug 2029

Sponsor

Lead sponsor
Sitala Bio LTDIndustry
Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). Geographic atrophy secondary to AMD is a condition where cells in the back part of the eye slowly die, causing a blurry, or missing spot in the centre of vision.

Conditions

  • Geographic Atrophy

Interventions

  • STL303Drug

    STL303 arm participants will receive a specific dose of STL303

  • PlaceboDrug

    Placebo arm participants will receive placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of rate of total EZ area lossTime frame: From baseline to Week 52

Locations

56 sites in 7 countries. Site status is shown where the registry gives one.

  • California Retina Consultants

    Bakersfield, California · Not yet recruiting

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Not yet recruiting

  • Retina Specialists of Colorado

    Aurora, Colorado · Not yet recruiting

  • Retina Group of New England, PC

    Waterford, Connecticut · Not yet recruiting

  • University Retina and Macula Associates, P.C.

    Lemont, Illinois · Not yet recruiting

  • Cumberland Valley Retina Consultants,P.C.

    Hagerstown, Maryland · Not yet recruiting

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland · Not yet recruiting

  • Ophthalmic Consultants of Boston

    Waltham, Massachusetts · Not yet recruiting

  • Long Island and Queens Vitreoretinal Consultants of NY, P.C.

    Hauppauge, New York · Not yet recruiting

  • Erie Retina Research

    Erie, Pennsylvania · Recruiting

  • Tennessee Retina, PC

    Nashville, Tennessee · Not yet recruiting

  • Retina Consultants of Texas

    Bellaire, Texas · Not yet recruiting

  • Star Vision Research

    Burleson, Texas · Recruiting

  • Retina Consultants of Texas

    Schertz, Texas · Not yet recruiting

  • Northeast Wisconsin Retina Associates

    Appleton, Wisconsin · Not yet recruiting

  • Eye Clinic of Wisconsin

    Wausau, Wisconsin · Not yet recruiting

  • Buenos Aires Macula S.A

    Buenos Aires, Buenos Aires, Argentina · Not yet recruiting

  • Centro Medico Viamonte SRL

    Buenos Aires, Buenos Aires, Argentina · Not yet recruiting

  • Centro de Ojos Quilmes

    Quilmes, Buenos Aires, Argentina · Not yet recruiting

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Not yet recruiting

  • Instituoto Oftalmologico de Buenos Aires S.A.

    Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Not yet recruiting

  • Centro Oftalmologico Dr. Charles S.A.

    Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Not yet recruiting

  • Centro Privado de Ojos

    Ciudad Autonoma Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Not yet recruiting

  • IMOC Instituto de Microcirugia Ocular Cordoba

    Córdoba, Córdoba Province, Argentina · Not yet recruiting

  • Centrovision Mendoza SA

    Mendoza, Mendoza Province, Argentina · Not yet recruiting

  • Centro de la Vision

    Salta, Salta Province, Argentina · Not yet recruiting

  • Grupo Laser Visión - Rosario Eximer Laser Visión

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia · Not yet recruiting

  • Sydney West Retina

    Westmead, New South Wales, Australia · Not yet recruiting

  • Queensland Eye Institute

    South Brisbane, Queensland, Australia · Not yet recruiting

  • Adelaide Eye and Retina Centre

    Adelaide, South Australia, Australia · Not yet recruiting

  • Cerulea Pty Ltd

    East Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Not yet recruiting

  • OFTEX, s.r.o.

    Pardubice, Prague, Czechia · Not yet recruiting

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Prague, Czechia · Not yet recruiting

  • Axon Clinical s.r.o.

    Prague, Prague, Czechia · Not yet recruiting

  • Szpital Swietego Lukasza S. A.

    Bielsko-Biala, Poland · Not yet recruiting

  • Specjalistyczny Osrodek Okulistyczny Oculomedica

    Bydgoszcz, Poland · Not yet recruiting

  • Prywatna Klinika Okulistyczna OFTALMIKA

    Bydgoszcz, Poland · Not yet recruiting

  • Clinical Medical Research Sp. z o.o.

    Katowice, Poland · Not yet recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.